Hormonal
Incretin-based pharmacotherapies (GLP-1, GIP, and triple agonists) significantly improve metabolic dysfunction-associated steatohepatitis (MASH) resolution and fibrosis regression compared to placebo, primarily through weight loss and insulin sensitization, with some agents showing direct hepatic benefits.
For patients with MASH, incretin-based therapies like Semaglutide (2.4mg weekly) are highly effective at resolving liver inflammation and improving fibrosis, often outperforming placebo in clinical trials. While gastrointestinal side effects are common, they can be managed with careful dosing and dietary adjustments, making these drugs a viable and potent option for those who struggle with lifestyle changes alone.
Incretin mimetics demonstrate multifarious benefits across the metabolic diseases spectrum with mounting evidence for their role in remitting steatopatitis and liver fibrosis. Weight loss and insulin sensitisation contribute, but additional mechanisms may also be engaged.
Why this rating
Based on multiple Phase 2 and 3 RCTs (LEAN, Newsome, ESSENCE, SYNERGY-NASH, Survodutide) showing statistically significant improvements in biopsy-proven MASH and fibrosis.
Source
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease
Harendran Elangovan et al. · Hepatology International · 2025
DOI 10.1007/s12072-025-10795-6
More from this paper
- Incretin therapies are associated with gastrointestinal side effects and potential risks of gallstone disease and pancreatitis, requiring careful patient selection and monitoring, particularly in those with a history of these conditions.Good
- Dual and triple receptor agonists (Tirzepatide, Survodutide, Retatrutide) show promise in MASH resolution, with some demonstrating superior efficacy to single GLP-1 agonists in weight loss and MASH resolution, though long-term hepatic outcomes are still being established.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →